Abivax welcomes Dr. Dominik Höchli to its Board of Directors

– FRANCE, Paris –  Abivax SA (EPA: ABVX / Nasdaq: ABVX), a biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the appointment of Dr.